Short answer
LB PHARMACEUTICALS INC (LBRX) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Unregistered share sale under Securities Act Section 4(a)(2) private-placement exemption.
LB PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Unregistered share sale under Securities Act Section 4(a)(2) private-placement exemption
- Investors provided private-placement representations; transaction lacked public offering or solicitation
- Shares carry registration and liquidity limitations for investors
- Potential dilution depends on the number and price of shares, not provided here
Item 7.01 · Regulation FD Disclosure
- July 29, 2026 press release announced a private placement
- Exhibit 99.1 contains the substantive financing terms and investor-relevant details
Item EX-99.1 · Exhibit EX-99.1
- $150 million private placement at $34.94 per share, supporting LB-102 development and corporate funding
- 3,577,560 shares plus pre-funded warrants for 715,513 shares, creating material potential dilution
- Proceeds targeted at LB-102 expansion into schizophrenia negative symptoms and Alzheimer’s agitation or psychosis
- Financing includes new and existing institutional investors, strengthening near-term funding for ongoing Phase 3 and Phase 2 trials
- Resale registration rights may increase future trading supply once registration becomes effective
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LB PHARMACEUTICALS INC 8-K filings
Get the next LBRX 8-K as it lands
Follow LBRX for push alerts, or ask the research agent what this filing means.